-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] In recent years, with the help of a series of favorable documents, domestic pharmaceutical innovation enterprises have begun to increa.
However, it is worth noting that the research and development of new drugs is not easy, and has always been characterized by high risks and high investme.
Therefore, in order to reduce research and development investment and improve innovation efficiency, many companies have begun to pay more and more attention to "License i.
It is reported that in the near future, many companies have developed new drugs through the introduction of innovative therapies and cooperati.
For example, a few days ago, Dongcheng Pharmaceutical announced that its wholly-owned subsidiary Andico and ImaginAb, I.
formally signed the "License Agreemen.
As the exclusive distributor, Andico will obtain the rights and related data stipulated under the ImaginAb patent rig.
, and further develop, register, manufacture and sell the target product zirconium Zr 89 crefmirlimab berdoxam in Chi.
According to the agreement, Antico will make an advance payment to ImaginAb after signing this agreement, and pay follow-up related fees when reaching milestones such as registration path confirmation, target product IND approval, target product BLA approval, e.
; Sales of no more than $1 billion and nodes exceeding $1 billion will be divided according to a fixed proportion of sal.
On May 18, Sino Biopharmaceutical announced that its subsidiary Chia Tai Tianqing has signed an agreement with Symphogen A/S to acquire the global rights to the LAG-3 monoclonal antibody Sym02Symphogen is a wholly-owned subsidiary of Servier and a key R&D center for antibodi.
Sym022 is a fully human recombinant LAG-3 monoclonal antibody, and it has shown good tumor suppressive potential in the preclinical sta.
At present, the product has completed two clinical phase I trials, and the clinical results show that it has good safety and tolerability whether used alone or in combination with other tumor immune checkpoint inhibito.
On May 2, Hansoh Pharmaceutical Group announced that its wholly-owned subsidiaries, Hansoh (Shanghai) Health and Jiangsu Hansoh Pharmaceutical (collectively, the Licensees), entered into an exclusive license agreement with NiKang TherapeuticsI.
Under the license agreement, the licensee obtained an exclusive license from NiKang Therapeutics to develop and commercialize NKT2152 for the treatment of tumors in China, including Hong Kong, Macau and Taiw.
At present, more and more domestic pharmaceutical companies have begun to introduce innovative projects through the "authorized introduction" model to accelerate the process of new drug listings, further enrich their product lines, and improve their competitiveness in innovati.
In this context, the innovative achievements of pharmaceutical companies have also accelerated, and a large number of new drugs will be approved for clinical trials and listed in the futu.
However, it should be noted that a large number of Chinese pharmaceutical companies are currently seeking to innovate through the license-in method, which is also causing some new drawbac.
For example, the cost of introducing innovative drugs from overseas is getting higher and higher, and the homogenization competition of domestic innovative drugs is becoming more and more serio.
In this regard, analysts believe that in the future, the innovation of pharmaceutical companies still needs to strengthen independent innovation, overcome the current dilemma of me-too, me-better, biosimilar, and fast follow, and transform from license in to license out, in order to continuously improve competitivene.
More market development spa.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Click to enter the exhibition page
However, it is worth noting that the research and development of new drugs is not easy, and has always been characterized by high risks and high investme.
Therefore, in order to reduce research and development investment and improve innovation efficiency, many companies have begun to pay more and more attention to "License i.
It is reported that in the near future, many companies have developed new drugs through the introduction of innovative therapies and cooperati.
For example, a few days ago, Dongcheng Pharmaceutical announced that its wholly-owned subsidiary Andico and ImaginAb, I.
formally signed the "License Agreemen.
As the exclusive distributor, Andico will obtain the rights and related data stipulated under the ImaginAb patent rig.
, and further develop, register, manufacture and sell the target product zirconium Zr 89 crefmirlimab berdoxam in Chi.
According to the agreement, Antico will make an advance payment to ImaginAb after signing this agreement, and pay follow-up related fees when reaching milestones such as registration path confirmation, target product IND approval, target product BLA approval, e.
; Sales of no more than $1 billion and nodes exceeding $1 billion will be divided according to a fixed proportion of sal.
On May 18, Sino Biopharmaceutical announced that its subsidiary Chia Tai Tianqing has signed an agreement with Symphogen A/S to acquire the global rights to the LAG-3 monoclonal antibody Sym02Symphogen is a wholly-owned subsidiary of Servier and a key R&D center for antibodi.
Sym022 is a fully human recombinant LAG-3 monoclonal antibody, and it has shown good tumor suppressive potential in the preclinical sta.
At present, the product has completed two clinical phase I trials, and the clinical results show that it has good safety and tolerability whether used alone or in combination with other tumor immune checkpoint inhibito.
On May 2, Hansoh Pharmaceutical Group announced that its wholly-owned subsidiaries, Hansoh (Shanghai) Health and Jiangsu Hansoh Pharmaceutical (collectively, the Licensees), entered into an exclusive license agreement with NiKang TherapeuticsI.
Under the license agreement, the licensee obtained an exclusive license from NiKang Therapeutics to develop and commercialize NKT2152 for the treatment of tumors in China, including Hong Kong, Macau and Taiw.
At present, more and more domestic pharmaceutical companies have begun to introduce innovative projects through the "authorized introduction" model to accelerate the process of new drug listings, further enrich their product lines, and improve their competitiveness in innovati.
In this context, the innovative achievements of pharmaceutical companies have also accelerated, and a large number of new drugs will be approved for clinical trials and listed in the futu.
However, it should be noted that a large number of Chinese pharmaceutical companies are currently seeking to innovate through the license-in method, which is also causing some new drawbac.
For example, the cost of introducing innovative drugs from overseas is getting higher and higher, and the homogenization competition of domestic innovative drugs is becoming more and more serio.
In this regard, analysts believe that in the future, the innovation of pharmaceutical companies still needs to strengthen independent innovation, overcome the current dilemma of me-too, me-better, biosimilar, and fast follow, and transform from license in to license out, in order to continuously improve competitivene.
More market development spa.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Click to enter the exhibition page
